Literature DB >> 33172932

SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells.

Sladjana Zagorac1, Alex de Giorgio1, Justin Stebbing1, Leandro Castellano2,3, Aleksandra Dabrowska1, Mark Kalisz4, Nuria Casas-Vila5, Paul Cathcart1, Angela Yiu1, Silvia Ottaviani1, Neta Degani6, Ylenia Lombardo1,7, Alistair Tweedie3, Tracy Nissan3, Keith W Vance8, Igor Ulitsky6.   

Abstract

In many tumors, cells transition reversibly between slow-proliferating tumor-initiating cells (TIC) and their differentiated, faster-growing progeny. Yet, how transcriptional regulation of cell-cycle and self-renewal genes is orchestrated during these conversions remains unclear. In this study, we show that as breast TIC form, a decrease in cell-cycle gene expression and increase in self-renewal gene expression are coregulated by SOX2 and EZH2, which colocalize at CpG islands. This pattern was negatively controlled by a novel long noncoding RNA (lncRNA) that we named Stem Cell Inhibitory RNA Transcript (SCIRT), which was markedly upregulated in tumorspheres but colocalized with and counteracted EZH2 and SOX2 during cell-cycle and self-renewal regulation to restrain tumorigenesis. SCIRT specifically interacted with EZH2 to increase EZH2 affinity to FOXM1 without binding the latter. In this manner, SCIRT induced transcription at cell-cycle gene promoters by recruiting FOXM1 through EZH2 to antagonize EZH2-mediated effects at target genes. Conversely, on stemness genes, FOXM1 was absent and SCIRT antagonized EZH2 and SOX2 activity, balancing toward repression. These data suggest that the interaction of an lncRNA with EZH2 can alter the affinity of EZH2 for its protein-binding partners to regulate cancer cell state transitions. SIGNIFICANCE: These findings show that a novel lncRNA SCIRT counteracts breast tumorigenesis by opposing transcriptional networks associated with cell cycle and self-renewal.See related commentary by Pardini and Dragomir, p. 535. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33172932     DOI: 10.1158/0008-5472.CAN-20-2612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  LncRNAs in breast cancer: a link to future approaches.

Authors:  Nikolaos Sideris; Paola Dama; Salih Bayraktar; Thomas Stiff; Leandro Castellano
Journal:  Cancer Gene Ther       Date:  2022-07-04       Impact factor: 5.987

2.  Long Noncoding RNA SCIRT Promotes HUVEC Angiogenesis via Stabilizing VEGFA mRNA Induced by Hypoxia.

Authors:  Lianze Gao; Jihong Yang; Yi Li; Keyu Liu; Huilin Sun; Jing Tang; Zhengyuan Xia; Liangqing Zhang; Zhe Hu
Journal:  Oxid Med Cell Longev       Date:  2022-06-03       Impact factor: 7.310

3.  The IncRNA SCIRT Promotes the Proliferative, Migratory, and Invasive Properties of Cervical Cancer Cells by Upregulating MMP-2/-9.

Authors:  Chunfeng Guan; Beibei Wang; Qixiu Dong
Journal:  J Oncol       Date:  2022-08-08       Impact factor: 4.501

4.  SCIRT lncRNA slows the formation of tumour initiating cells in breast cancer.

Authors:  Alex de Giorgio; Leandro Castellano
Journal:  Oncoscience       Date:  2021-06-03

5.  Exosomal lncRNA SCIRT/miR-665 Transferring Promotes Lung Cancer Cell Metastasis through the Inhibition of HEYL.

Authors:  Zhengyang Wang; Minmin Lin; Lulu He; Hongyan Qi; Jing Shen; Kejing Ying
Journal:  J Oncol       Date:  2021-07-24       Impact factor: 4.375

Review 6.  Non-coding RNA in cancer.

Authors:  Huiwen Yan; Pengcheng Bu
Journal:  Essays Biochem       Date:  2021-10-27       Impact factor: 8.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.